Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

Core Viewpoint - Verrica Pharmaceuticals Inc. has appointed Chris Chapman as the new Chief Commercial Officer, aiming to enhance the commercialization of its products, particularly YCANTH for molluscum contagiosum and VP-315 for basal cell carcinoma [2][5]. Company Overview - Verrica Pharmaceuticals is focused on developing dermatology therapeutics for skin diseases that require medical interventions [5]. - The company's flagship product, YCANTH (VP-102), is the first FDA-approved treatment for molluscum contagiosum, affecting approximately 6 million people in the U.S., primarily children [4][5]. - YCANTH is also being developed for the treatment of common warts, addressing a significant unmet need in medical dermatology [5]. Leadership Appointment - Chris Chapman brings over 25 years of commercial experience in the pharmaceutical industry, having previously served as Chief Commercial Officer at Dermavant Sciences [2][3]. - His experience includes launching VTAMA for adult plaque psoriasis and leading the U.S. Prescription Business for Galderma [3]. Product Details - YCANTH is a proprietary drug-device combination that allows for precise topical dosing and is administered by healthcare professionals [4]. - The product has shown positive results in two Phase 3 clinical trials involving approximately 500 patients, demonstrating safety and efficacy [4]. - Approximately 250 million lives are eligible for YCANTH coverage by insurance, with commercially insured patients paying $25 per treatment visit [4]. Pipeline Development - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315, targeting non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [5].